Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EZZ Life Science Holdings Limited	
ABN	83 608 363 604	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Glenn Walter Cross
Date of last notice	27 August 2024

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect				
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Penelope Marshall (Ms Marshall is the director's spouse)				
Date of change	6 December 2024				
No. of securities held prior to change	Direct				
	40,000 Fully paid ordinary shares 15,000 Performance Rights				
	Indirect 26,000 Fully paid ordinary shares held by Penelope Marshall				
Class	Performance Rights/FPOS				
Number acquired	5,000 FPOS				
Number disposed	5,000 Performance Rights				

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3Y Change of Director's Interest Notice

Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Non-cash – estimated value \$2.67
No. of securities held after change	<b>Direct</b> 45,000 Fully paid ordinary shares 10,000 Performance Rights
	Indirect 26,000 Fully paid ordinary shares held by Penelope Marshall
Nature of change  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Issue of FPOS on vesting of performance rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 – \*Closed period

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

12 December 2024

<sup>+</sup> See chapter 19 for defined terms.

Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EZZ Life Science Holdings Limited
ABN	83 608 363 604

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Hao Huang
Date of last notice	27 August 2024

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.			
Date of change	6 December 2024		
No. of securities held prior to change	15,000 Performance Rights		
Class	Performance Rights/FPOS		
Number acquired	5,000 FPOS		
Number disposed	5,000 Performance Rights		
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Non-cash – estimated value \$2.67		
No. of securities held after change	10,000 Performance Rights 5,000 Fully Paid Ordinary shares		

<sup>+</sup> See chapter 19 for defined terms.

Nature of change	Issue	FPOS	on	vesting	of	performance
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	rights					

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

12 December 2024

Appendix 3Y Page 2 01/01/2011

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EZZ Life Science Holdings Limited
ABN	83 608 363 604

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ivan Oshry
Date of last notice	27 August 2024

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Terry Oshry (Ms Oshry is the director's spouse)	
Date of change	6 December 2024	
No. of securities held prior to change	Direct 10,000 Fully paid ordinary shares 15,000 Performance Rights  Indirect 11,000 Fully paid ordinary shares held by Terry Oshry	
Class	Performance Rights/FPOS	
Number acquired	5,000 FPOS	
Number disposed	5,000 Performance Rights	

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3Y Change of Director's Interest Notice

Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Non-cash – estimated value \$2.67
No. of securities held after change	<b>Direct</b> 15,000 Fully paid ordinary shares 10,000 Performance Rights
	Indirect 11,000 Fully paid ordinary shares held by Terry Oshry
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Issue of FPOS on vesting of performance rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 – \*Closed period

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

<sup>12</sup> December 2024

<sup>+</sup> See chapter 19 for defined terms.